Cagrilintide alone: RENEW 1 phase 3 results and what to expect
Reviewed 20 sourcesPublished by PepVault
Cagrilintide alone in phase 3: what RENEW 1, 2 and 4 test, the 11.8% bar REDEFINE 1 set, how it compares with semaglutide, and when results are due.

- Last reviewed
- Sources
- 20
- Questions
- 6
- Compounds
- 3
The short answer
RENEW 1 has not reported as of November 20, 2026. The phase 3 trial gives about 300 adults with obesity or overweight and no diabetes weekly cagrilintide 2.4 mg, Novo Nordisk's amylin drug, or placebo for 64 weeks. Novo expects results in the second half of 2027. The bar to meet: the 11.8% weight loss cagrilintide alone reached in REDEFINE 1 for people who stayed on treatment.
Evidence: One phase 2 dose-finding trial in 906 people (Lancet 2021), a small phase 2 diabetes trial and a 302-person cagrilintide-alone arm of the phase 3 REDEFINE 1 trial (NEJM 2025, with Novo's sub-analysis), all funded by Novo Nordisk; RENEW 1, 2 and 4 have not reported, and cagrilintide is not approved anywhere.

What does RENEW 1 test?
RENEW 1 is the first phase 3 trial built to test cagrilintide on its own, with no GLP-1 drug beside it. Adults with obesity (a BMI of 30 or more), or a BMI of 27 or more with a weight-related condition such as high blood pressure, and no diabetes, take a weekly shot of cagrilintide or a placebo (a dummy shot) for 64 weeks, with lifestyle counselling1. Two of every three get cagrilintide, and neither they nor the trial staff know who gets which1.
The primary endpoint, the one result the trial is built to test, is the percentage change in body weight from week 0 to week 641. Novo Nordisk named the dose when it started the programme: cagrilintide 2.4 mg, in about 300 people4. People who had ever taken an amylin drug, or any weight-loss medicine in the 180 days before screening, could not join1. Two sister trials run beside it.
| Trial | Who | Length | Primary endpoint | Size and status |
|---|---|---|---|---|
| RENEW 11 | Obesity or overweight, no diabetes | 64 weeks | Weight change at week 64 vs placebo | About 300 at 40 sites in 10 countries; enrolment closed |
| RENEW 22 | Obesity or overweight with type 2 diabetes | 64 weeks | Weight change at week 64 vs placebo | About 330 at 67 sites in 11 countries; enrolment closed |
| RENEW 43 | Obesity or overweight, no diabetes | 26 weeks | Weight change at week 26, two presentations vs placebo | About 285 at 36 sites in 6 countries; recruiting |
RENEW 2 is the diabetes trial, and its design has a twist: up to 30% of its participants may stay on a GLP-1 medicine they have taken at a stable dose for at least a year, so part of the trial tests amylin added on top2. RENEW 4 is a device study. It compares two presentations of cagrilintide, one of them in a device that also carries a placebo matched to semaglutide, which reads like the two-chamber CagriSema pen; that reading is ours, not the registry's3.

PepVault for iPhone
Keep your protocol in PepVault
PepVault reminds you of a weekly shot on its day and logs each dose with its date, and its weight chart marks the day you started and every dose change, so you can set your own weeks beside a trial's.
7 days free on the yearly plan for new subscribers.
What is amylin, and why test cagrilintide alone?
Amylin is a hormone the pancreas releases together with insulin after a meal. It slows how fast food leaves the stomach, holds back glucagon (the hormone that tells the liver to release sugar) and tells the brain you have eaten enough15. One amylin drug is already approved: pramlintide (Symlin), for diabetes, injected before each major meal15.
Cagrilintide is a long-acting amylin analogue, a built copy of the hormone made to last. In people its half-life, the time for half a dose to clear, measured 159 to 195 hours, about a week, in a trial that gave it with semaglutide, which is why it is a weekly shot16.
Try it
How Cagrilintide builds up
An estimate from a half-life of about 7 days, one dose a week for four weeks. The shape of the level, not a measurement.
Novo already pairs it with semaglutide as CagriSema. The case for cagrilintide alone is choice: a different route to fullness for people who want or need something other than a GLP-1. Novo is testing that directly in a separate, smaller trial of people who stopped a GLP-1 drug because of stomach side effects, where the primary endpoint is how many are on cagrilintide's standard dose or higher at 26 weeks17.
What did the earlier cagrilintide trials show?
Three trials past phase 1 have reported weight results for cagrilintide alone, all funded by Novo. Two ways of counting appear below. The treatment-policy number counts everyone who started, including people who stopped the drug; the trial-product number estimates the result if everyone stayed on it, and runs a little higher.
| Trial | Who and how long | Weight change on cagrilintide | Placebo or comparator |
|---|---|---|---|
| Phase 2 dose-finding, 2021910 | 906 adults without diabetes (706 on cagrilintide), 26 weeks, doses 0.3 to 4.5 mg | −9.5% on 2.4 mg; −10.8% on 4.5 mg (registry's posted means) | −3.0% on placebo; −8.5% on liraglutide 3.0 mg (same) |
| Phase 2 in type 2 diabetes, 202311 | 30 adults on cagrilintide 2.4 mg, 32 weeks | −8.1% | −5.1% on semaglutide 2.4 mg; −15.6% on the pair |
| REDEFINE 1, phase 3, 2025678 | 302 adults without diabetes on cagrilintide 2.4 mg, 68 weeks | −11.8% (trial product); −11.5% (treatment policy) | Placebo −2.3% and −3.0%; semaglutide 2.4 mg alone −16.1% and −14.9% |
The REDEFINE 1 arm is the number RENEW 1 inherits. In that arm, 31.6% of people lost 15% or more of their weight if they stayed on treatment, against 4.7% on placebo6. Tolerability was the quiet headline: nausea made 1.0% stop cagrilintide for good, against 0.1% on placebo6, and at week 68, 82.5% were still on the full 2.4 mg dose, against 70.2% on semaglutide alone7.
REDEFINE 1 was designed to test CagriSema against placebo; the cagrilintide-alone figures come from Novo's post hoc sub-analysis of a smaller arm, presented at EASD in September 20256. RENEW 1 is the first trial to make cagrilintide alone its main question.
Cagrilintide vs semaglutide: what would count as a good RENEW 1 result?
Set the bar before the number lands. Semaglutide 2.4 mg, the drug in Wegovy, lost 14.9% of body weight at 68 weeks in STEP 1, against 2.4% on placebo, counting everyone, and 50.5% of people lost 15% or more12. No earlier trial puts cagrilintide alone above that. The question is whether it lands close, with fewer people put off by nausea.
- Weight: about 11% to 12% at 64 weeks would confirm REDEFINE 1, whose arm reached 11.5% counting everyone and 11.8% for people who stayed on6. RENEW 1 is four weeks shorter, so a number slightly under REDEFINE 1's would still be on track.
- The 15% mark: around 31% of people reaching 15% or more, as in REDEFINE 16. STEP 1's semaglutide figure was 50.5%12.
- Stopping for side effects: REDEFINE 1's 1.0% who stopped for nausea, against 0.1% on placebo, is the figure to hold6. STEP 1 counted every stomach side effect, not nausea alone: 4.5% stopped semaglutide for one, against 0.8% on placebo12. The two are different measures, so read the gap as a direction, not a size.
- Nausea itself: 31% had nausea on 2.4 mg in the phase 2 trial, against 18% on placebo10; in STEP 1, 44% did on semaglutide, against 17%13.
- RENEW 2: weight loss runs lower with type 2 diabetes. Semaglutide 2.4 mg lost 9.6% at 68 weeks in STEP 2, against 3.4% on placebo14, and cagrilintide alone lost 8.1% in 32 weeks in the small diabetes trial11.
A result in that range would make cagrilintide the first amylin-only weight drug with a full phase 3 case: less weight loss than semaglutide, gentler on the stomach. A result well above 12% would change the comparison with semaglutide outright.
Commonly reported: early fullness and smaller portions within the first weeks, nausea that is milder than on a GLP-1 and comes mostly after a step-up, and some redness or itching where the shot goes in, which the phase 2 trial also recorded10.
When will RENEW 1 results come out?
The registry's primary completion date for RENEW 1 is May 11, 2027, an estimate of when the last participant reaches the week-64 weigh-in, not a results date1. RENEW 2 follows on May 12 and RENEW 4 on May 1823. Novo said in its report of November 4, 2026 that it expects phase 3 results from RENEW 1 and 2 in the second half of 20275.
| Date | What could happen |
|---|---|
| May 11 to 18, 2027 | Primary completion of RENEW 1, 2 and 4, the registry's estimates123 |
| May 18 to 21, 2027 | European Congress on Obesity, Munich; its abstract deadline, January 15, falls before the data exist18 |
| June 18 to 21, 2027 | American Diabetes Association Scientific Sessions, Washington, D.C.19 |
| Second half of 2027 | Novo's stated window for RENEW 1 and 2 results5 |
| September 21 to 24, 2027 | EASD Annual Meeting, Budapest; the REDEFINE 1 cagrilintide data were first shown at EASD in 2025206 |
The most likely first sight is a Novo company announcement with the topline numbers, as with REDEFINE 17, then a full presentation at a meeting. Novo also expects to start a high-dose cagrilintide phase 3 in the fourth quarter of 20265, so RENEW 1 may not be the last word on the dose.
PepVault reminds you of a weekly shot on its day and logs each dose with its date, and its weight chart marks the day you started and every dose change, so you can set your own weeks beside a trial's. Set reminders in PepVault
Has RENEW 1 reported yet?
Not reported as of November 20, 2026. None of the three registry records has posted results123, and Novo's latest report lists RENEW 1 and 2 as future milestones5. When Novo releases the topline, this section will carry the average weight change at week 64 counting everyone and counting those who stayed on, the share reaching 10% and 15%, the rate of stopping for side effects, and RENEW 2's weight and blood sugar numbers beside them.
Cagrilintide is investigational: the registry describes it as a new medicine doctors cannot prescribe yet3. For the drug itself, PepVault's cagrilintide page in the library covers its mechanism, half-life and side effects, the cagrilintide vs semaglutide comparison sets the two side by side, and the REDEFINE 1 and STEP 1 study pages hold the trials behind the bars above. The pair's own approval is the CagriSema FDA decision guide.
Sources
- ClinicalTrials.gov NCT07220642. RENEW 1: efficacy and safety of cagrilintide for weight management in participants with overweight or obesity (phase 3; sponsor Novo Nordisk A/S). Record updated August 6, 2026. clinicaltrials.gov
- ClinicalTrials.gov NCT07220759. RENEW 2: efficacy and safety of cagrilintide for weight management in participants with overweight or obesity and type 2 diabetes (phase 3; sponsor Novo Nordisk A/S). Record updated November 16, 2026. clinicaltrials.gov
- ClinicalTrials.gov NCT07745504. RENEW 4: a placebo-controlled comparability study of two presentations of cagrilintide (phase 3; sponsor Novo Nordisk A/S). Record updated September 4, 2026. clinicaltrials.gov
- Novo Nordisk A/S, Form 6-K: Financial report for the period 1 January 2025 to 30 September 2025 (R&D update: RENEW programme initiated). November 5, 2025. sec.gov
- Novo Nordisk A/S, Form 6-K: Financial report for 1 January to 30 September 2026 (anticipated key R&D milestones). November 4, 2026. sec.gov
- Novo Nordisk. Novo Nordisk presents phase 3 data for next-generation amylin cagrilintide, leading to advancement into dedicated clinical programme (company announcement, EASD 2025). September 16, 2025. ml-eu.globenewswire.com
- Novo Nordisk A/S, Form 6-K: CagriSema demonstrates superior weight loss in adults with obesity or overweight in the REDEFINE 1 trial (company announcement No 99/2024). December 20, 2024. sec.gov
- Garvey WT et al. Coadministered cagrilintide and semaglutide in adults with overweight or obesity (REDEFINE 1). N Engl J Med. 2025;393(7):635-647. PubMed 40544433
- Lau DCW et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a dose-finding phase 2 trial. Lancet. 2021;398(10317):2160-2172. PubMed 34798060
- ClinicalTrials.gov NCT03856047. Cagrilintide dose-finding phase 2 trial in people with overweight or obesity (sponsor Novo Nordisk A/S): posted results, July 18, 2023. clinicaltrials.gov
- Frias JP et al. Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes: a phase 2 trial. Lancet. 2023;402(10403):720-730. PubMed 37364590
- Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. PubMed 33567185
- ClinicalTrials.gov NCT03548935. STEP 1, semaglutide 2.4 mg in adults with overweight or obesity (sponsor Novo Nordisk A/S): posted results, adverse events. clinicaltrials.gov
- Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021;397(10278):971-984. PubMed 33667417
- SYMLINPEN (pramlintide acetate) injection prescribing information, sections 1, 2 and 12.1. AstraZeneca. DailyMed, version 18, August 2024. dailymed.nlm.nih.gov
- Enebo LB et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg: a phase 1b trial. Lancet. 2021;397(10286):1736-1748. PubMed 33894838
- ClinicalTrials.gov NCT07607587. Tolerability of cagrilintide in people with obesity who stopped GLP-1 therapies because of gastrointestinal side effects (sponsor Novo Nordisk A/S). clinicaltrials.gov
- ECO2027: the 34th European Congress on Obesity, Munich, 18-21 May 2027; abstract deadline 15 January 2027 (congress site). eco2027.org
- American Diabetes Association. 2027 Scientific Sessions, Washington, D.C., June 18-21, 2027 (save the date). professional.diabetes.org
- EASD. 63rd EASD Annual Meeting, Budapest, 21-24 September 2027. easd.org
Newsletter · Weekly
The weekly peptide briefing.
New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.